TrialAnnals of clinical and translational neurology2024

Safety, pharmacokinetics, and pharmacodynamics of nomlabofusp (CTI-1601) in Friedreich's ataxia.

Russell Clayton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.